Seattle Genetics' Adcetris scores first-line lymphoma nod, setting up 'biggest opportunity' yet
admin 21st March 2018 Uncategorised 0Seattle Genetics officially has the first-line Adcetris nod in advanced classical Hodgkin lymphoma that it’s been gunning for. Now, it’ll be up to the company to capitalize on what CEO Clay Siegall has called “the biggest market opportunity that we have yet looked at.”
More: Seattle Genetics' Adcetris scores first-line lymphoma nod, setting up 'biggest opportunity' yet
Source: fierce